Drug design, development and therapyJul 28, 2026

Real-world weight loss with different GLP-1 medicines in the All of Us study

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Aug 3, 2026

Abstract

Five glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with weight loss in a diverse US population of adults with obesity.

The study evaluated the effectiveness of GLP-1RAs for weight loss among adults with and without type 2 diabetes.
Weight loss outcomes observed in real-world settings may differ from those reported in clinical trials.
The analysis included a diverse population, reflecting various demographics and health backgrounds.
The findings suggest potential variability in weight loss effectiveness among different GLP-1RAs.

Simplified

To assess the real-world associations of five glucagon-like peptide-1 receptor agonists (GLP-1RAs) with weight loss in a diverse US population of adults with obesity, with and without type 2 diabetes, and whether the relative ordering of weight loss observed in trials is mirrored in routine practice.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

0%of authors

0 of 3

authors report competing interests

3 report none

PubMed

Featured in

GLP-1 Therapies

GLP-1 TherapiesIssue #48

Stop the drug, regain the weight: pooled data puts the average rebound at 7%

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

Stop the drug, regain the weight: pooled data puts the average rebound at 7%

The brain region that explains why blocking and activating the same receptor both cause weight loss

1 week ago7 studies

GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study

2 weeks ago7 studies

Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients

3 weeks ago7 studies

Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study

4 weeks ago7 studies

Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients

5 weeks ago7 studies

Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group

6 weeks ago8 studies

New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients

7 weeks ago7 studies

GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery

8 weeks ago7 studies

Semaglutide linked to reduced cigarette craving in 24 smokers

9 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief